EAU PCa 2018: Local Treatment in M+ PCa

Milan, Italy (UroToday.com) In this session the speakers gave an interesting talk on local treatment in patients with metastatic prostate cancer. According to the EAU guidelines, metastatic disease is defined as M1a – nonregional lymph nodes, M1b – bone metastases, and M1c- other sites.

EAU PCa 2018: mCRPC: Which Drugs and in What Sequence?

Milan, Italy (UroToday.com) Dr. Cornford gave an overview of the therapy for metastatic castrate resistant prostate cancer (MCRPC). CRPC is defined as disease progression despite castrate levels of testosterone (<=50 ng/dl). Failure of androgen deprivation therapy (ADT) occurs due to sustained androgen receptor signaling despite castrate levels of testosterone.

EAU PCa 2018: Treatment of mHSPC

Milan, Italy (UroToday.com) This was an interesting talk on treatment of metastatic hormone sensitive prostate cancer (MHSPC) patients. Dr. Maresburger began the session stating that when considering treatment for these patients we should ask several important questions: When is the proper time to start therapy? Do we need to use combined androgen blockade? Combine other treatments? and what do we do when there is evident progression? In a Cochrane review analyzing early vs. deferred androgen deprivation therapy (ADT) for the treatment of advanced prostate cancer, the results clearly demonstrated that early treatment has a significant benefit.

EAU PCa 2018: Update on Trial Results in mHSPC

Milan, Italy (UroToday.com) Dr. Morselaar gave an update on the recent trials in metastatic hormone sensitive prostate cancer (MHSPC). Ever since the discovery of androgen deprivation therapy (ADT) by Charles B. Huggins in 1966, hormonal therapy has been a key factor in the treatment of advanced prostate cancer. However, for many years now, there has been an attempt to add additional therapies in addition to ADT, to improve outcomes. In 2013, the French GETUG-15 trial compared ADT to ADT + docetaxel.1 Although the trial demonstrated an advantage in clinical progression free survival for the docetaxel group, no advantage was seen in overall survival. Furthermore, no difference was seen in the metastases rate in both groups.

EAU PCa 2018: Focal Therapy in 2018: Still Experimental?

Milan, Italy (UroToday.com) Dr. Emberton gave an eloquent talk on the role of focal therapy for prostate cancer in the current era. According to Dr. Emberton, focal therapy is a heuristic that describes an attempt to reduce the rate of positive margins, to individualize treatment, to improve the therapeutic ratio, to create oncological consistency, and to uphold a long-standing urological tradition.

EAU PCa 2018: Who is the Optimal Candidate for Local Treatment? (Surgery vs. Radiotherapy)

Milan, Italy (UroToday.com) Dr. Mottet and Dr. Bossi presented which patient is the optimal candidate for local treatment which is not an easy question to answer, and it is not clear whether it should be based on treatment efficacy, treatment contraindication, or technical feasibility.

EAU PCa 2018: Salvage Radical Prostatectomy

Milan, Italy (UroToday.com) This was a session on local surgical salvage treatment for post-radiotherapy biochemical recurrence, and on surgical salvage lymphadenectomy. The purpose of radical salvage prostatectomy includes secondary local surgery with curative intent. We aim to improve the long-term cancer-specific survival, to maintain continence and potency, and to have a low percentage of surgery associated complications. Additionally, we want to prevent and treat local complications.
Page 1 of 3